Skip to main content
. Author manuscript; available in PMC: 2017 May 30.
Published in final edited form as: Sci Transl Med. 2017 Feb 1;9(375):eaah3438. doi: 10.1126/scitranslmed.aah3438

Fig. 3. Viral burden in CHIKV-infected mice treated with CTLA4-Ig and anti-CHIKV mAb.

Fig. 3

Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single intraperitoneal injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb, or a combination of 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. (A) Infectious virus in joints and serum quantitated by focus-forming assay on day 5 after infection. (B and C) Real-time qRT-PCR analysis of viral RNA levels in the ipsilateral (left) and contralateral (right) ankles and left wrist at days 7 and 28 after infection. Results are pooled from two independent experiments with n = 10 per treatment group for viral RNA data and n = 8 for focus-forming assay data. Data represent the median ± SEM. *P < 0.05, **P < 0.005, ***P < 0.0005 (Kruskal-Wallis with Dunn’s post hoc analysis).